The microRNA-15a-PAI-2 axis in cholangiocarcinoma-associated fibroblasts promotes migration of cancer cells by Utaijaratrasmi, Penkhae et al.
RESEARCH Open Access
The microRNA-15a-PAI-2 axis in
cholangiocarcinoma-associated fibroblasts
promotes migration of cancer cells
Penkhae Utaijaratrasmi1, Kulthida Vaeteewoottacharn2,5, Takaaki Tsunematsu6, Pranisa Jamjantra9,
Sopit Wongkham2,5, Chawalit Pairojkul3, Narong Khuntikeo4,5, Naozumi Ishimaru6, Yongyut Sirivatanauksorn7,
Ananya Pongpaibul8, Peti Thuwajit9, Chanitra Thuwajit9* and Yasusei Kudo6*
Abstract
Background: Cholangiocarcinoma (CCA) has an abundance of tumor stroma which plays an important role in
cancer progression via tumor-promoting signals. This study aims to explore the microRNA (miRNA) profile of
CCA-associated fibroblasts (CCFs) and the roles of any identified miRNAs in CCA progression.
Methods: miRNA expression profiles of CCFs and normal skin fibroblasts were compared by microarray. Identified
downregulated miRNAs and their target genes were confirmed by real-time PCR. Their binding was confirmed by a
luciferase reporter assay. The effects of conditioned-media (CM) of miRNA mimic- and antagonist-transfected CCFs
were tested in CCA migration in wound healing assays. Finally, the levels of miRNA and their target genes were
examined by real-time PCR and immunohistochemistry in clinical CCA samples.
Results: miR-15a was identified as a downregulated miRNA in CCFs. Moreover, PAI-2 was identified as a novel
target gene of miR-15a. Recombinant PAI-2 promoted migration of CCA cells. Moreover, CM from miR-15a
mimic-transfected CCFs suppressed migration of CCA cells. Lower expression of miR-15a and higher expression
of PAI-2 were observed in human CCA samples compared with normal liver tissues. Importantly, PAI-2
expression correlated with poor prognosis in CCA patients.
Conclusions: These findings highlight the miR-15a/PAI-2 axis as a potential therapeutic target in CCA patients.
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Tumor microenvironment
Background
Cholangiocarcinoma (CCA) is a tumor of bile duct epi-
thelium which arises from cholangiocytes or the epithe-
lial cells lining the biliary tree [1]. It is a major health
problem in the endemic area of Opisthorchis viverrini in-
fection in Southeast Asia especially in the northeastern
part of Thailand [2]. It is well known that CCA predomin-
antly shows an abundant desmoplastic reaction in the
tumor stroma [3]. These alpha-smooth muscle actin
(ASMA) positive stromal cells were correlated with the
degree of tumor fibrosis in CCA tissues [4] and levels were
significantly related to poor prognosis of CCA patients [5].
Cancer-associated fibroblasts (CAFs) are the major
component in the stromal environment of several car-
cinomas including CCA and mainly affect tumor pro-
gression through the induction of cancer cell growth,
invasion, and metastasis [6, 7]. The current authors have
previously reported that CAFs in CCA tissues have a
high expression of ASMA and the level of ASMA-
positive CAFs was correlated with poor patient survival
[5]. In addition, the conditioned-media (CM) from CAFs
induced CCA cell proliferation by driving cancer cells
into the G2/M phase of the cycle. Previous exploration
of the gene expression profile of CAFs isolated from
CCA tissues found a set of genes which encoded
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secreted tumorigenic protein products that could act in
a paracrine manner to promote cancer progression [8].
MicroRNAs (miRNAs) are small, non-coding single-
stranded RNAs and one of the key post-transcriptional
gene expression regulators [9, 10]. They act as negative
regulators to control gene expression via imperfect or
perfect binding to their target mRNAs. miRNA regulation
in CAFs has been studied in several cancers [11–17].
Microarray analyses identified specific expression of
several miRNAs in CAF within urinary bladder cancer
and breast cancer compared with fibroblasts from non-
cancer tissues [12, 16]. The impact of miRNAs underlying
gene expression control in CCA-associated fibroblasts
(CCFs) has not so far been reported. This study aimed to
explore the miRNA profiles of CCFs by miRNA microar-
rays and to identify the aberrant target mRNAs; in par-
ticular, those that encode secreted tumorigenic proteins.
Methods
Cell culture
Human CCA cell lines, KKU-213 and KKU-055 were cul-
tured in Hams F-12 Nutrient Mixture (Invitrogen) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS). Antibiotics including 0.1 U/ml penicillin G sodium
and 0.1 mg/ml streptomycin (Gibco BRL), and 5 mg/ml
amphotericin B (Amphotret™, Bharat Serums and Vaccines
Limited Ltd.) were added to prevent microbial contamina-
tions. CCFs were isolated from CCA tissues obtained from
patients who underwent hepatectomy at Srinakarind
Hospital. The protocol was approved by the Khon Kaen
University Ethics Committee for Human Research
(HE521209 and HE571283). Each patient was informed
about tissue collection and signed the consent form.
The pieces of tissue were submerged in antibiotic-
containing Dulbecco’s Modified Eagle Media (DMEM;
Gibco BRL) with 10% FBS for 30-60 min to reduce mi-
crobial contamination during the process of sample col-
lection and transfer. The samples were rinsed with 1X
phosphate buffer saline (PBS) and cut into small pieces
(2 mm3). Fresh complete medium, 10% FBS-containing
DMEM with 20 mM HEPES (Gibco BRL), was used to
wash out cell debris. Pieces of tissue were transferred to
fresh culture vessels and allowed to adhere at 37 °C in a
5% CO2 in air incubator. After fibroblast-like cells
emerged from beneath the tissue pieces, the adherent cells
were trypsinized with 0.25% trypsin/EDTA (Gibco BRL).
The complete medium was replaced every 3 days. Cells
were subcultured for 7 to 23 passages and used for the re-
ported studies. Normal skin fibroblasts (SFs) were ob-
tained from human tissues and cultured in a similar way.
Immunocytochemistry
To identify primary cultures of fibroblasts from contami-
nating cancer cells, the absence of epithelial markers
and the presence of fibroblast-related mesenchymal
markers were checked. Cytokeratin 19 (CK19), an epi-
thelial marker; vimentin (VIM) and alpha-smooth
muscle actin (ASMA), mesenchymal markers, were se-
lected. CCA cell lines were used as the positive controls
for CK19 detection. Cells were cultured for 24 h in 96-
well plates and fixed with 4% paraformaldehyde for
15 min and permeabilized with 1% Triton X-100 for
1 min. Non-specific binding was blocked by 1% BSA in
1X PBS for ASMA and 5% FBS in 1X PBS for VIM and
CK19. The mouse anti-human CK19 antibody (1:100 di-
lution; SC-6278, Santa Cruz Biotechnologies Inc.),
mouse anti-human VIM antibody (1:500 dilution; SC-
6260, Santa Cruz Biotechnologies Inc.), and mouse anti-
human ASMA antibody (1:200 dilution; Sigma-Aldrich)
were used. The primary antibody was incubated for 3 h
at room temperature. After washing, goat anti-mouse
IgG-Cy3 (Jackson Immunoresearch Laboratories Inc.)
was added for 1 h at room temperature followed by
adding Hoechst stain (Invitrogen). The signals were de-
tected under an inverted fluorescence microscope.
Fibroblast conditioned-media collection
CM from CCFs and SFs was collected by growing cells
in complete medium for 4 days until cells reached about
90% confluency. Then, cells were washed twice with PBS
and incubated in DMEM with 2% FBS for 48 h. After
that, CM was collected, centrifuged at 4 °C 1000 g for
5 min to remove cell debris, sterile filtered and stored
at -80 °C until use.
Wound healing migration assay
CCA cells were cultured in 6-well plates until they
reached approximately 90% confluence. A reference line
was drawn in the center of the underside of the plate.
The cell monolayer was scratched using a sterile 1000-μl
pipette tip followed by washing three times with fibro-
blast CM, serum-free medium or complete medium.
The scratched areas indicated by reference lines were re-
corded at the beginning and 24 h after treatment. The
migration efficiency was expressed as the percentage
closure of the wound area calculated by the following
formula:
%wound healing ¼ wound space at 0 h−wound space at 24 h
wound space at 0 h
 100
Cell proliferation assay
Cells were suspended with 5000 cells/well in 96-well
plates for 24 h. Culture medium was then changed to
100 μl/well of 10% FBS in DEMEM or CM and the plate
was incubated for 24 h and 48 h in a 5% CO2 incubator at
37 °C. Cell viability was measured by MTS assay (Promega,
Mandison, WI) following manufacturer’s instruction. The
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absorbance was detected at 490 nm with a microplate
reader. The assays were performed in duplicate.
For checking the effect of recombinant target proteins,
8000 cells/well were suspended for 24 h. Then, culture
medium was changed to fresh medium with or without
2 μg/ml of human recombinant WNT10B protein or
2 μg/ml of human recombinant PAI-2 protein in 96-well
plates and the plates were incubated for 24 h. Finally,
proliferating cell numbers were determined using the
cell-counting kit 8 (CCK-8) solution (Dojindo Molecular
Technique, Inc.). 10 μl of CCK-8 solution was added to
each well and incubated for 1 h in a 5% CO2 incubator
at 37 °C. The number of proliferating cells was deter-
mined by absorbance measured at 450 nm using a mi-
croplate reader at 0, 24 and 48 h.
miRNA microarray analysis
miRNA expression profiles of CCFs and SFs were ana-
lyzed by the TaqMan® Array Human MicroRNA Card A
or Card B Set v2.0 (Applied Biosystems). Total RNA was
extracted by MirVana® microRNA isolation kit (Applied
Biosystems). Then 480 ng of total RNA was converted to
cDNA by Megaplex™ RT stem-loop primer pools A
and Megaplex™ RT stem-loop primer pools B (Applied
Biosystems) following the instruction manual. RT reac-
tion was performed using Megaplex™ RT primers, human
pools A, B and TaqMan® MicroRNA Reverse Transcription
Kit (Applied Biosystems). cDNAs obtained were amplified
with TaqMan® Human MicroRNA Array A, B and
TaqMan® Universal Master Mix II, no UNG using Real
time PCR ABI7900HT (Applied Biosystems). The amp-
lification reactions were monitored using SDS software
v2.3, and data analyzed with RQ Manger 1.2. The fold
changes of each CCF sample were compared with aver-
age expression of SFs after normalization with U6
small nuclear RNA (snRNA). Fold changes >2-fold
were taken to indicate up-regulated miRNAs and ≤0.5-
fold down-regulated miRNAs.
Real-time PCR
To evaluate miRNAs, total RNA was isolated from
cells using the MirVana® microRNA isolation kit
(Applied Biosystems). The isolates were quantified and
their purity was evaluated using a spectrophotometer.
The cDNA was synthesized from 10 ng of total RNA
using a TaqMan® MicroRNA Assay and a TaqMan®
MicroRNA Reverse Transcription Kit (Applied Biosystems).
Synthesized cDNA was amplified with a TaqMan®
MicroRNA Assay and a TaqMan® Universal Master Mix
II, no UNG (Applied Biosystems) using an ABI 7300
real time PCR system (Applied Biosystems) for 45 cycles
of denaturation at 95 °C for 15 s, and annealing and ex-
tension at 60 °C for 60 s. Data were normalized with
U6 and each analysis was performed three times. The
average of three trials was used for statistical analysis.
ANOVA was used for comparison of variables in more
than two groups and a Student’s T-test was used for
comparisons between two groups. A P-value <0.05 was
considered statistically significant.
To evaluate mRNAs, 1 μg of total RNA was converted
to cDNA by ReverTra Ace-α® (Toyobo Co; Ltd) and
50 ng of cDNA was amplified with SYBR® Premix Ex
Taq™ II (Takara Bio Inc.). The reaction was performed
using a DNA Engine Opticon Real-Time Thermal Cycler
(MJ Research, Inc.) under the following conditions; heat-
denaturation at 95 °C for 10 min followed by cycled
amplification at 95 °C for 15 s and 60 °C for 45 s for 50 cy-
cles. The primer sequences are shown in Additional file 1:
Table S1 and Additional file 2: Table S2. Data were nor-
malized with GAPDH and each analysis was performed
three times. The average of three trials was used for
statistical analysis. The ANOVA test was used for com-
parison of variables in more than two groups and the
Students T-test was used for two groups. A P-value
<0.05 was considered statistically significant.
miRNA target gene prediction
The potential target genes of miR-15a and miR-148a
were determined using TargetScanHuman 6.2 (http://
targetscan.org/). To further reduce the false target
genes in the analysis, target genes that were co-
predicted target genes by at least two of the three data
sets were considered as potential targets. According to
these algorithms, protein array chip data and mRNA
microarray chip data from a previous report [8] were
used for screening the most suitable candidate target
genes. Candidate targeted genes which encoded the se-
creted proteins, were selected as targeted genes from
overlapping at least 2 of 3 algorithms or TargetScan
and have been found in a previous report [8] and/or
previous reports from PubMed data.
Transfection of miRNA mimic and miRNA inhibitors
The hsa-miRNAs mimics were commercially available
(Ambion®, Thermo Scientific). The product numbers
MH10235 and MH1026 were used as a miR-15a and
miR148a mimics. The negative control miRNA mimic
(mirVana™ miRNA mimic negative control #1) was used
as the scrambled miRNA mimic. The anti-mir-15a and
miR-148a inhibitors, MC10235 and MC10263, were ob-
tained from Ambion®, Thermo Scientific, whereas a
negative control inhibitor, mirVana™ miRNA inhibitor
negative control #1, were used as the scrambled miRNA
inhibitor. Cells (CCFs) were transfected with 5 nM hsa-
miR-15a, hsa-miR-148a and used as the negative control
miRNA mimic using Lipofectamine RNAi Max (Invitrogen)
according to the manufacturer’s protocol. Cells (SFs)
were transfected with 75 nM of miR-15a inhibitor,
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miR-148a inhibitor and negative control miRNA inhibitor
using Lipofectamine RNAi Max. Efficiency of miRNA in-
hibition or mimic transfection was confirmed at the
mRNA level by real-time PCR.
Luciferase reporter assay
The full-length 3′-UTR of human VEGFA, PAI-2, and
WNT10B was amplified by PCR from genomic DNA
and cloned at the EcoRI site into pmirGLO vector
(Promega). For PAI-2, we also generated a deletion
mutant of putative miR-15a binding sequences,
TGCTGCT, from full-length 3′-UTR of human PAI-2
construct. We used a deletion mutant of pmirGLO-
PAI-2 as a negative control. This construct was con-
firmed by sequencing. For luciferase activity analysis,
this vector was co-transfected with miRNA duplex in
293 T cells using DharmaFECT Duo transfection re-
agent (Thermo Fisher Scientific) for 72 h, and lucifer-
ase assays were performed with the Dual-Luciferase
reporter system (Promega) according to the manufac-
turer’s instructions. Luminescent signal was quantified
by a luminometer (Glomax; Promega), and each value
from the firefly luciferase construct was normalized
against the Renilla luciferase assay.
Double chamber migration assay
24-well cell culture inserts with 8 μM pores (3097,
Falcon, Becton Dickinson) were used. After trypsiniza-
tion, 1.5 × 105 CCA cells were resuspended in CM under
different conditions and placed in the upper compart-
ments of the cell culture inserts for 7 h. In an additional
assay, 2 μg/ml of human recombinant WNT10B protein
(7196-WN-010, R&D systems) or 2 μg/ml of human re-
combinant PAI-2 protein (P6129, Abnova) was added
after trypsinization and before plating the cells on the
upper compartments of the inserts. After incubation at
37 °C, the cells that migrated through the membrane to
the lower side were fixed with formalin and then stained
by hematoxylin. The number of migrated cells were de-
termined by counting the cells on the lower side of the
filter under a microscope at ×100 magnification. The fil-
ters were assayed 3 times and 3 fields were randomly se-
lected and counted for each assay.
Western blot analysis
Sample protein concentrations were measured by the
Coomassie Plus™ (Bradford) Assay Kit (Thermo scien-
tific), and 30 μg total protein/lane were subjected to
electrophoresis on 10% polyacrylamide gels followed by
electroblotting onto polyvinylidene fluoride (PVDF)
membranes. The membranes were blocked with 3% milk
in TBS-T and incubated overnight at 4 °C with anti-
human PAI-2 polyclonal antibody (Santa Cruz). The
membranes were then washed with TBS-T and incubated
with HRP-conjugated goat anti-rabbit IgG antibody
(ab6721, Abcam, Cambridge, MA, USA) and the pro-
teins visualized using SuperSignal West Pico Chemi-
luminescent Substrate under Gel Document Synene
(Syngene). β-actin was used as a loading control. For
CM, PAI-2 level was quantitated by densitometric ana-
lysis of the protein bands against that of the total protein
loading using ImageJ software (National Institutes of
Health, Bethesda, MD, USA).
Immunohistochemistry in CCA tissues
Seventy-four cases of intrahepatic CCA were used in
this study. All patients were preoperatively chemo- and
radiotherapy naïve. All tissue samples with their clini-
cohistopathological records were obtained from the
Department of Pathology, Faculty of Medicine Siriraj
Hospital, Mahidol University Faculty of Medicine and
Departments of Biochemistry, Pathology, and Surgery
Faculty of Medicine, Khon Kaen University under the
approval of the Ethics Committee for Human Research
(HE521209 and HE571283) and Siriraj Institutional
Review Board (si287/2011). The demographic data of
all the patients in this study are summarized (Table 1).
Tissue sections were deparaffinized in xylene, rehy-
drated in descending grades of ethanol. Heat-induced
antigen retrieval was performed in a 95 °C water bath
for 1 h by incubation with 0.05 M EDTA buffer pH 8.0.
Endogenous peroxidase activity was blocked with
methanol containing 0.3% H2O2 for 30 min followed by
blocking non-specific binding sites with 3% bovine
serum albumin in 1× PBS for 1 h at room temperature.
The sections were treated with polyclonal human PAI-2
antibody (Santa Cruz, 1:100) at 4 °C overnight. The
EnVision+ System-HRP labelled polymer anti-rabbit
(K4003, Dako, Carpinteria, CA, USA) secondary anti-
body was used. The immunoreactive signal was devel-
oped by Liquid DAB+ Substrate Chromogen System
(K3467, Dako) and counterstained with hematoxylin.
Tissue slides were dehydrated, mounted, and further
analyzed using a ScanScope® scanner. Sections were
semi-quantitatively evaluated and scored by two pathol-
ogists; both were blinded to the clinical parameters. For
grading the immunohistochemical results, the staining
intensities were recorded separately for cancer cells and
CCFs. The I scale of intensity: 0 (negative), 1 (weak), 2
(moderate), and 3 (strong) was used whereas the per-
centage of positive cells (P) in the area was scored as: 0,
1 (1-25%), 2 (26-50%), 3 (51-75%) and 4 (>75%). The
multiplication of P and I resulted in the total score of
0-12. The PAI-2 immunohistochemical score of more
than 6 was classified as the high expression group,
whereas those with ≤ 6 total score was graded as the
low expression group.
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Statistical analyses
The differences between the test and the control condi-
tions in this study were statistically analyzed from the
mean ± SD of three independent experiments. Chi-
square or Fisher’s exact tests were used to analyze the
clinicopathohistological relevance of PAI-2 in clinical
CCA samples. The Kaplan-Meier method and Log-Rank
tests were used for survival analysis. Univariate and
multivariate Cox regression analyses of potential factors
were performed to identify the significant predictors. All
the statistical analyses were performed using SPSS 17.0
statistical software. P-values of less than 0.05 were con-
sidered to be statistically significant.
Results
Characterization of CCFs isolated from CCA tissues
The CCFs (B149 and C096) and normal control SFs
(SFA3 and SFA5) showed spindle-like shapes in contrast
to the cobble-stoned shape of KKU-213 CCA cells
(Fig. 1a). In CCFs and SFs, immunocytochemical analysis
revealed negative staining of the epithelial marker CK19
and positive staining of VIM (Fig. 1b). CCFs showed
higher expression of ASMA than SFs (Fig. 1b). The CM
from both CCFs revealed a significantly greater ability to
induce migration in CCA cells than normal SFA3 and
SFA5 cells at 3 and 6 h (Fig. 1c). CM from CCFs showed
no effect on proliferation of CCA cells (Fig. 1d). The
expression of CCF-related genes that were previously re-
ported [8], included a disintegrin and matrix metallopro-
teinase 12 (ADAM12), amphiregulin (AREG), epiregulin
(ER), jagged 1 (JAGL1), platelet-derived growth factor-
alpha (PDGFA), secretogranin 2 (SCG2), periostin (PN),
fibroblast activation protein (FAP), fibroblast specific pro-
tein (FSP), ASMA, and VIM (Additional file 3: Figure S1).
ASMA and PDGFA expression levels were higher in CCFs
than in SFs (Additional file 3: Figure S1).
Comparing miRNA expression profiles between CCFs
and SFs
The PCR-based miRNA array was performed to measure
the miRNA profiling in 2 CCFs compared to 2 SFs.
Among 677 human miRNAs, 162 miRNAs were up-
regulated (≥ 2-fold) and 93 miRNAs were downregulated
(≤ 0.5-fold) in both CCFs (B149 and C096) compared to
the expression of either SFA3 or SFA5 cells. The down-
regulated miRNAs comparing B149 cells to SFs (B149/
SFs) and C096 cells to SFs (C096/SFs) were 17 and 91
miRNAs (Fig. 2a) respectively. Among them, 15 miRNAs
(CCFs/SFs) were commonly downregulated in CCFs
compared to both SFs after normalization with U6
snRNA (Fig. 2a and Additional file 4: Figure S2). From a
literature review, among 15 miRNAs, miR-15a, miR-
148a and miR-486 targeted several secreted proteins
(Additional file 5: Table S3). The expression levels of
Table 1 Univariate analysis and Cox regression multivariate analysis of PAI-2 in cancer cells in clinical CCA samples and patient
clinicopathological parameters
Parameters (no. of cases) Univariate Multivariate
PAI-2 in cancer cells P-value OR
(95% CI)
P-value
High Low
High PAI-2 expression (72) 45 27 – 3.452 (1.188-10.030) 0.023
Age (y) (72) < 60 24 13 0.808 1.00 (0.499-2.003) 1.000
≥ 60 21 14
Gender (72) Male 25 17 0.625 1.291 (0.683-2.443) 0.432
Female 20 10
Tumor size (cm) (67) < 5 15 9 0.790 1.375 (0.698-2.705) 0.357
≥ 5 29 14
Tumor staging (72) I - III 8 10 0.093 0.963 (0.359-2.579) 0.940
IV 37 17
Histological type (72) WD 23 9 0.220 – 0.008
MD 6 4 1.000 2.034 (0.915-4.519) 0.081
PD 2 5 0.095 4.414 (1.1610-12.106) 0.004
Pap 14 9 1.000 6.199 (1.754-21.909) 0.005
Vascular invasion (51) Absence 18 16 0.065 0.405 (0.190-0.866) 0.020
Presence 14 3
LN metastasis (72) Absence 28 20 0.439 2.078 (0.925-4.670) 0.077
Presence 17 7
WD well differentiated, MD moderately differentiated, PD poorly differentiated, Pap papillary, OR odd ratio, 95% CI 95% confidence interval, LN lymph node
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these miRNAs in CCFs and SFs were examined and only
miR-15a and miR-148a showed decreased levels in all
CCFs in comparison to those in SFs (Fig. 2b). Moreover,
B149/SFs and C096/SFs revealed 145 and 4 up-regulated
miRNAs, with 13 miRNAs in common after normalization
with U6 snRNA (Additional file 6: Figure S3A and B). In
this study, we focused on downregulated miRNAs in-
cluding miR-15a and miR-148a.
Identification of miR-15a target genes in CCFs
To predict the potential mRNA targets of miR-15a and
miR-148a, TargetScan miRNA target prediction database
was used. Taken together, these lists of target genes with
the overexpressed genes in CCFs studied by cDNA
microarray [8] and highly expressed proteins in the CM
(unpublished data), propose several target genes of
interest for miR-15a including VEGFA, PAPPA, NRG1,
FGF2, PAI-2, AXIN2, FGF7, and WNT3A (Fig. 3a) and
for miR-148a are TNFRSF6B, CD62L (L-selectin), TGFA,
WNT1, and WNT10B (Additional file 7: Figure S4A).
The real-time PCR results revealed that only VEGFA
and PAI-2 were up-regulated in CCFs, in comparison
with SFs (Fig. 3b). WNT10B was also up-regulated in
CCFs, compared with SFs (Additional file 7: Figure S4B).
It has already been shown that WNT10B is a target of
miR-148a in CAFs [17]. We confirmed that WNT10B
expression was downregulated by ectopic overexpression
of miR-148a and was upregulated by the miR-148a in-
hibitor (Additional file 7: Figure S4C and D). In this
study, the focus was on PAI-2 and VEGFA as targets of
miR-15a. The expression levels of PAI-2 and VEGFA
after transfection of miR-15a mimic in CCFs were
Fig. 1 Characterization of CCFs. a Morphology of CCFs, SFs and CCA cells. Original magnification of 40×. b Immunocytochemical staining of
CK19, VIM and ASMA. The KKU-213 CCA cell line was used as a positive control of CK1 expression. Original magnification of 400×. c The effect of
CCFs-CMs and SFs-CMs on migration of CCA cells in a wound healing assay. At 3, 6, 12, and 18 h, the % of wound area was measured. Bars represent
mean ± SD of three measurements. *P < 0.05 (compared to 10% FBS DMEM). #P < 0.05 (compared to SF_CM). d The effect of CCFs-CMs and SFs-CMs
on proliferation of CCA cells. Bars represent mean ± SD of two measurements
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examined. Reduced expressions of PAI-2 and VEGFA
were observed by miR-15a mimic-transfection com-
pared to control miRNA transfection (Fig. 3c and
Additional file 8: Figure S5A). Moreover, we con-
firmed that the miR-15a inhibitor increased the ex-
pression of VEGFA and PAI-2 in SFs (Fig. 3d and
Additional file 8: Figure S5B).
The mRNA expression levels of these two target genes
of miR-15a were checked in CCFs, SFs and CCA cell
lines (KKU-213 and KKU-055). Expressions of PAI-2
and VEGFA in CCFs were higher than those in SFs
(Fig. 3e and Additional file 8: Figure S5C). Interestingly,
expression of PAI-2 in CCF was higher than that in
CCA cells (Fig. 3e and f ), suggesting that CCFs may be
a major source of PAI-2 protein, although cancer cells
could also produce PAI-2. In the following experi-
ments, we focused on the miR-15a-PAI-2 axis.
miR-15a-PAI-2 axis in CCFs promotes migration of CCA
To investigate whether miR-15a can directly target PAI-
2 by interacting with its 3′-UTR in vitro, we amplified
the full-length of 3’-UTR from genomic DNA. The puta-
tive miR-15a binding sequences are TGCTGCT. We
deleted a deletion mutant of putative miR-15a binding
sequences from full-length 3′-UTR of human PAI-2
construct and used as a negative control. The wild type
and mutant 3′-UTR of PAI-2 were cloned and inserted
downstream of a luciferase reporter gene. Subsequently,
miR-15a mimic or control miRNA was co-transfected
with these reporter vectors into 293 T cells. The miR-
15a mimic significantly decreased the relative luciferase
activity of the wild type 3′-UTR reporter vector, but not
statistical significance for the deletion mutant (Fig. 4a).
As PAI-2 is a secreted protein, we confirmed the ex-
pression of PAI-2 in CM from C096 cells (Fig. 4b). To
examine the effects of PAI-2 on the proliferation and
migration of CCA cells, we used rPAI-2 protein. The
rPAI-2 had the capability to increase migration during
6-12 h of exposure compared with untreated controls
with a statistical significance in CCA cells (Fig. 4c and d).
Notably, rPAI-2 treatment did not promote proliferation
(Additional file 9: Figure S6A) or invasion (Additional
file 9: Figure S6B, see method in Additional file 10).
The level of miR-15a in CCFs was increased after
transfection without any cytotoxic effect (data not
shown). Next, we examined the effects of CM from
Fig. 2 Comparing miRNA expression profiles between CCFs and SFs. a Vane diagram and lists of down-regulated miRNAs showing the fold
change in CCFs versus SFs. b Real-time PCR of miR-15a, miR-148a and miR-486 expression levels in 5 CCFs and 2 SFs. Bars represent mean ± SD of
three measurements
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miR-15a mimic-transfected C096 CCFs on the migra-
tion of KKU-055 and KKU-100 CCA cells by the
wound healing assay. Ectopic overexpression of miR-
15a mimic in C096 cells downregulated PAI-2 expres-
sion in CM (Fig. 4b). Moreover, the CM from miR-15a
mimic-transfected C096 CCFs significantly inhibited
the migration of CCA cells in comparison with that
from scrambled miRNA transfected cells (Fig. 4e).
Interestingly, rPAI-2 treatment partially rescued the
inhibitory effect of migration by CM from miR-15a
mimic-transfected CCFs in both CCA cell lines (Fig. 4e).
PAI-2 expression in clinical CCA tissues
In 14 CCA and 2 normal liver tissues, expressions of
miR-15a and PAI-2 were examined by real-time PCR.
Expression of miR-15a in CCA cases was lower than its
average expression in normal liver tissues (Fig. 5a).
PAI-2 expression was higher in most CCA cases com-
pared with normal liver tissues (Fig. 5b).
Seventy-two clinical samples of CCA cases were en-
rolled in the immunohistochemistry experiment with the
clinicopathological data including sex, age, clinical sta-
ging, histological grading, vascular invasion, lymph node
Fig. 3 Identification of miR-15a target genes. a Four criteria for finding the candidate target genes of miR-15a. b The expression levels of eight
predicted target genes of miR-15a in 6 CCFs compared to 2 SFs. Bars represent mean ± SD of three measurements. c Expression of PAI-2 in miR-15a mimic-
transfected C096 cells by real-time PCR. Scrambled miRNAs were used as negative control miRNA. d Expression of PAI-2 in miR-15a inhibitor transfected
SFs. *P< 0.05 compared to control. e Expression of PAI-2 in 6 CCFs, 2 SFs and 2 CCA cell lines. Bars represent means ± SD of three measurements. f PAI-2
expression was examined by Western blot analysis in 2 SFs, 5 CCFs, and 2 CCAs. β-actin was used as a loading control
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(LN) metastasis and overall survival time (Table 1). The
median age of patients was 59±8.2 y with a 1.4:1 male:
female ratio. The average tumor size was 5 cm for the
largest diameter of the mass. Around 75% of total cases
were classified in late stage of the disease (stage IV)
and vascular invasion and LN metastasis were found in
33% of the enrolled cases. The immunostaining re-
vealed positive signals in tumor tissues with different
degrees of expression (Fig. 5c). Approximately 63% of
CCA cases (45 of 72) had high PAI-2 levels. Univariate
analysis showed that the level of PAI-2 in cancer cells
was not correlated with any clinicopathological parame-
ters, but the Cox regression multivariate analysis showed
significant correlations of PAI-2 independent of the other
parameters (Table 1). The multivariate analysis revealed
the potential of a high PAI-2 level being a risk factor in
CCA patients at around 3.452-fold (P-value = 0.023).
Moreover, high expression of PAI-2 was significantly
correlated with histological type and vascular invasion.
CCA patients with a high PAI-2 in cancer cells had a
median survival time of 249 d compared with 395 d in
those with low levels. Kaplan-Meier analysis showed a
Fig. 4 The miR-15a-PAI-2 axis promotes migration of CCA cells. a Luciferase assay of pmirGLO vector containing wild type 3’-UTR of PAI-2 and its
deletion mutant of putative miR-15a binding sequences in mature miR-15a-transfected cells. The data were normalized to scrambled miRNA
transfected cells. Bars represent mean ± SD of five measurements. b Secreted PAI-2 in CM from miR-15a mimic-transfected C096 CCFs examined
by Western blot analysis. CMs from cells with no transfection and scrambled miRNA-transfected cells were used as a control. Ponceau S staining
of each sample on the membrane was shown. Densitometric analysis of PAI-2 normalized against the total protein loading is shown. c The effect
of rPAI-2 on migration of KKU-213 CCA cells was examined by a wound healing assay at different time points. Graphs show % of wound areas in
KKU-213 cells with or without rPAI-2 in. Bars represent mean ± SD of three measurements. d The effect rPAI-2 on CCA cells in the chamber migration
assay. Graphs show the number of migrated cells with or without rPAI-2 treatment at 7 h. Bars represent mean ± SD of three measurements. e The
effect of CM from miR-15a mimic or scrambled miRNA transfected C096 CCFs on the migration of CCA cells with or without rPAI-2. The migration was
evaluated at 12 h by a wound healing assay as previously described. Bars represent mean ± SD of three measurements. *P < 0.05
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statistically significant correlation of a high PAI-2 level
with short survival time (Fig. 5d, P-value = 0.006).
Discussion
For decades, CAFs have been recognised for their impact
in regulating the aggressive phenotypes of cancer cells in
particular through the paracrine activity of secreted sub-
stances on cancer cells. In CCA in Thailand, which is
commonly caused by the infection of the liver fluke,
Opisthorchis viverrini, CAFs have been investigated for
their activated phenotype by positive ASMA expression
as a poor prognostic marker correlated with short
patient survival time [5], recently supported by the find-
ing that aggressive phenotype CAFs in intrahepatic CCA
can be identified as a useful predictor for prognosis [18].
Using a mouse model, CCA-bearing animals were tar-
geted with apoptosis induction specifically for CAFs
within the tumor masses and the results revealed that
CCA growth was attenuated, implicating CAFs in the
control of cancer progression [19]. These studies, taken
together, provide new evidence that CAFs can serve as
potential therapeutic targets in CCA.
Most of the evidence published in the field of CAFs in
CCA showed the function of paracrine substances able
Fig. 5 Expression of PAI-2 in CCA tissues. a Real-time PCR of miR-15a in 14 CCA tissues and 2 normal liver tissues. Bars represent mean ± SD of
three measurements. Dashed line represents the level of average expression in normal liver tissues. b Real-time PCR of PAI-2 in 14 CCA tissues
and 2 normal liver tissues. Bars represent mean ± SD of three measurements. c Immunohistochemical staining of PAI-2 in clinical CCA samples.
Representative images of high and low expression of PAI-2 are shown. Scale bar: 200 μm. d The survival analysis by Kaplan-Meier test was per-
formed using 3-y as the cut-off. e The proposed mechanism of miR-15a-PAI-2 axis in microenvironment of CCA tissue
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to activate CCA cells [8, 20, 21]. The aberrant produc-
tion of secreted proteins from CAFs has been identified
by us as the results of an alteration in gene expression
[8]. Although epigenetic alterations and chromosomal al-
terations can be found associated with CAFs of different
cancer types [22–24], several studies have also shown that
alterations of miRNAs in CAFs are common and are in-
volved in multiple functions in tumorigenesis and malig-
nant progression [25–30]. In this study, changes of
miRNA expression of CCA CCFs were investigated and
miR-15a and miR-148a were selected as the most promis-
ing down-regulated miRNAs. The role of miR-15a in
CAFs in controlling cancer growth, invasion and resist-
ance to therapy has been identified in prostate cancer
[13]. miR-15a, together with miR-16, can target several
onco-products i.e. Bcl-2, Bmi-1, Wnt family members,
and VEGF, IL-6 [31]. Moreover, VEGFA has been shown
to be the target of miR-15a [32, 33]. This is the first study
to identify PAI-2 as a target of miR-15a. Herein, elevated
expression of PAI-2 was observed in CCFs, in comparison
with SFs. Moreover, rPAI-2 significantly promoted the mi-
gration of CCA cells. Suppression of PAI-2 production
from CCFs by transfection of miR-15a mimic attenuated
the migration of CCA cells. These findings suggest that
the miR-15a-PAI-2 axis in CCFs may be involved in the
progression of CCA. Indeed, human CCA tissues with low
expression of miR-15a showed high expression of PAI-2.
Importantly, patients with high expression of PAI-2
showed poor prognosis.
Moreover, PAI-2 secreted from mast cells can up-
regulate the expression of ASMA in dermal fibroblasts
[34]. This is an important finding which may explain the
fibrotic disorder in diseases of excessive fibrosis in the
dermis. The precise mechanism by which PAI-2 activates
ASMA has not been elucidated. It is proposed that PAI-
2 may impact cellular activities by changing in the cell
surface, including the stability of membrane receptors
and extracellular ligands [34]. Hence it is tempting to
speculate that PAI-2 secreted into the microenvironment
of CCA may activate the expression of ASMA not only
in the stromal fibroblasts but also in cancer cells. This
may be one of the mechanisms by which PAI-2 can
activate CCA cell migration. Another possibility is the
finding in urothelial carcinoma that invasive properties
were significantly correlated to the up-regulated expres-
sion of ASMA in stromal fibroblasts and loss of mem-
branous E-cadherin and increased Snail, Slug, Zeb1 in
cancer cells [35]. These altered characters are the
hallmark of the ‘epithelial-to-mesenchymal’ transition
phenomenon, increasing cancer cells’ ability to mi-
grate and invade. This previous report supports our
findings in CCA that ASMA positive stroma (as well
as high PAI-2 in tumor microenvironment) correlate
with poor prognosis.
In several types of cancer, miRNA expression profiling
of CAFs has been reported [28, 36]. In head and neck
cancer, miR-7, miR-196 and miR-335 are significantly
up-regulated in CAFs compared with normal fibroblasts,
and miR-7 is involved in cancer growth and migration
[28]. In prostate cancer, the altered miRNA profile of
normal control fibroblasts treated with IL-6 resembled
that of CAFs [36]. In breast cancer, 11 dysregulated miR-
NAs were identified in CAFs: 3 up-regulated miRNAs,
miR-221-5p, miR-31-3p, and miR-221-3p, and 8 down-
regulated miRNAs, miR-205, miR-00b, miR-200c, miR-
141, miR-101, miR-342-3p, let-7 g, and miR-26b [16].
Here, miR-15a and miR-148a were downregulated in
both in vitro CCFs and clinical CCA tissues. This finding
is supported by previous reports that miR-148a was
downregulated in CAFs from oral cancers compared to
normal fibroblasts. Investigation of miR-148a function
demonstrated that overexpression of miR-148a in CAFs
significantly impaired the migration and invasion of can-
cer cells by directly targeting WNT10B [17, 37]. In our
study, miR-148a was also downregulated and WNT10B
was identified as a target gene in CCFs.
The urokinase plasminogen activation (uPA) system is
a crucial pathway for tumor invasion and establishment
of metastasis. A systematic review evaluating the expres-
sion of uPA, urokinase plasminogen activator receptor
(uPAR), PAI-1/SerpinE1 and PAI-2/SerpinB2 on primary
esophageal, the gastro-esophageal junction, and gastric
adenocarcinomas was reported and indicated that a high
expression of uPA, uPAR and PAI-1 was associated with
a higher risk of disease and poorer prognosis [38]. PAI-1
and PAI-2 are efficient endogenous inhibitors of uPA.
They are key players in the breakdown of extracellu-
lar matrix and basement membrane [39]. Here, high
expression of PAI-2 was observed and correlated with
poor prognosis in CCA patients. PAI-2, previously de-
tected in peripheral blood lymphocytes of CCA pa-
tients was proposed as part of a set of markers of
independent and statistically significant predictors of
patient survival [40]. We suggest that in addition to
lymphocytes, cancer cells and CCFs may be additional
sources of PAI-2 released into the microenvironment
of CCA tissues. Importantly, PAI-2 can act in both
autocrine and paracrine manners to activate migration
of CCA cells.
Base on the association of liver fluke Opisthorchis
viverrini infection and CCA oncogenesis, it is interesting
to see up-regulated PAI-2 in CCA. PAI-2 has been re-
ported to be related to the recruitment of M2 macro-
phages in the nematode infection of the intestine
[41]. M2 cells are accepted for a certain time to in-
duce the progressiveness of CCA [42]. Moreover,
Schistosoma japonicum granulomas induced mouse
liver PAI-2 expression [43]. It is tempting to speculate
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that Opisthorchis viverrini infection may stimulate
PAI-2 overproduction released into the CCA micro-
environment which may directly induce cancer cell
migration (as reported in our study) and at the same
time encourage a tumor-promoting environment by
modulating infiltrating immune cells. This remains to
be tested.
Conclusions
In conclusion, this is the first report on miRNA profiling
in CCFs. Downregulation of miR-15a in CCFs leads to
the increased secretion of PAI-2 and VEGFA (Fig. 5e).
Our findings provide the opportunity for exploring
therapies aimed at reconstituting the miR-15/PAI-2 axis
in CCA and the potential of using PAI-2 levels as a poor
prognosis marker in these patients.
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